Adam Fless

Adam Fless is a Partner & Managing Director at AlixPartners, the global consulting and performance-improvement firm, based in its San Francisco office. He rejoined AlixPartners in January 2021 to help lead its private-equity practice, and now co-leads the firm's Americas Healthcare & Life Sciences practice and its Americas M&A and Transaction Advisory work. He describes himself as an enterprise value-creation leader who has split more than 25 years roughly evenly between execution-focused consulting/advisory roles and hands-on private-equity fund operations and board work, bringing "a Private Equity mindset of ownership, sustainability and urgency."

From 2017 to 2021 Fless was a Managing Director at Paine Schwartz Partners — the largest private-equity firm dedicated to sustainable food-chain investing (~$6.5B AUM, offices in New York and San Mateo). Appointed in January 2017 to the newly created "Managing Director – Portfolio Performance" role, he built and led the firm's value-creation / "Portfolio Excellence" function, running operational due diligence on prospective investments and driving performance improvement across portfolio companies (manufacturing, supply chain, value engineering, pricing, and sales-force effectiveness). This operating-partner mandate — not a deal-sourcing or angel-investing one — is the source of the stub data.

Before Paine Schwartz, Fless spent roughly 11 years in private equity as a value-creation leader at KKR Capstone, where he was a Director from July 2010 to January 2017. Earlier he was a Director at AlixPartners (2004–2010) and an Associate at A.T. Kearney (1998–2003), working across food/restaurant, retail/consumer, automotive, industrial, and services sectors internationally.

He holds an MBA from London Business School and a BA in Economics and International Trade from the University of Waterloo (Canada).

• Not a thesis-driven capital allocator. Fless does not write checks or set investment theses; he is an operating/value-creation and transaction-advisory executive. Any "investment stage / check size / thesis" framing for him personally would be fabricated.
• What he actually does: supports private-equity clients (and formerly a PE fund's portfolio) on "diligence, margin, and growth transformation programs" — procurement, design-to-value, supply-chain optimization, cost management, carve-outs, and post-merger integration.
• Sector lens: deepest in food/agriculture supply chain (from his Paine Schwartz years), plus healthcare & life sciences, industrials, infrastructure, and business services.
• Value-creation levers he emphasizes: manufacturing/service-delivery efficiency, procurement and supply chain, value engineering, pricing, sales-force effectiveness, and strategic partnerships — i.e., improving already-owned or soon-to-be-acquired companies rather than early-stage bets.
• Paine Schwartz house thesis he operated within (firm-level, for context): two themes — *productivity & sustainability* (enhancing agricultural productivity while limiting resource use) and *health & wellness* (access to healthier, safer, more nutritious food).